The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Hypertensive Myocardial Fibrosis and Diastolic Dysfunction: Another Model of Inflammation?
Abstract
Excessive myocardial fibrosis deteriorates diastolic function in hypertensive hearts. Involvement of macrophages is suggested in fibrotic process in various diseased situations. We sought to examine the role of macrophages in myocardial remodeling and cardiac dysfunction in pressure-overloaded hearts. In Wistar rats with suprarenal aortic constriction, pressure overload induced perivascular macrophage accumulation and fibroblast proliferation with a peak at day 3, decreasing to lower levels by day 28. Myocyte chemoattractant protein (MCP)-1 mRNA was upregulated after day 1, peaking at day 3 and returning to insignificant levels by day 28, whereas transforming growth factor (TGF)-β induction was observed after day 3, with a peak at day 7, and remained relatively elevated at day 28. After day 7, concentric left ventricular (LV) hypertrophy developed, associated with reactive fibrosis and myocyte hypertrophy. At day 28, echocardiography showed normal LV fractional shortening but decreased ratio of early to late filling wave of transmitral Doppler velocity, and hemodynamic studies revealed elevated LV end-diastolic pressure, suggesting normal systolic but impaired diastolic function. Chronic treatment with an anti-MCP-1 monoclonal neutralizing antibody inhibited not only macrophage accumulation but also fibroblast proliferation and TGF-β induction. Furthermore, the neutralizing antibody attenuated myocardial fibrosis, but not myocyte hypertrophy, and ameliorated diastolic dysfunction without affecting blood pressure and systolic function. In conclusion, roles of MCP-1-mediated macrophage accumulation are suggested in myocardial fibrosis in pressure-overloaded hearts through TGF-β-mediated process. Inhibition of inflammation may be a new strategy to prevent myocardial fibrosis and resultant diastolic dysfunction in hypertensive hearts.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Atherosclerosis--an inflammatory disease
Ross, R. (1999) · New England Journal of Medicine · doi:10.1056/nejm199901143400207 · Cited by 21,725
Transforming Growth Factor β in Tissue Fibrosis
Epstein, F. H., Border, W. A., & Noble, N. A. (1994) · New England Journal of Medicine · doi:10.1056/nejm199411103311907 · Cited by 3,069
Desmoulière, A., Geinoz, A., Gabbiani, F., & Gabbiani, G. (1993) · The Journal of cell biology · doi:10.1083/jcb.122.1.103 · Cited by 2,243
Congestive heart failure in subjects with normal versus reduced left ventricular ejection fraction
Vasan, R. S., Larson, S., Benjamin, E. J., Evans, J. C., Reiss, C. K., & Levy, D. (1999) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(99)00118-7 · Cited by 1,331
Alexander, R. W. (1995) · Hypertension · doi:10.1161/01.hyp.25.2.155 · Cited by 785
Mechanisms and Models in Heart Failure: A Combinatorial Approach
Mann, D. L. (1999) · Circulation · doi:10.1161/01.cir.100.9.999 · Cited by 773
Kuwahara, F., Kai, H., Tokuda, K., Kai, M., Takeshita, A., Egashira, K., & Imaizumi, T. (2002) · Circulation · doi:10.1161/01.cir.0000020689.12472.e0 · Cited by 609
Self-citationChemokines and atherosclerosis
Reape, T. J., & Groot, P. H. E. (1999) · Atherosclerosis · doi:10.1016/s0021-9150(99)00346-9 · Cited by 504
Myocardial fibrosis: functional significance and regulatory factors
Weber, K. T., Brilla, C. G., & Janicki, J. S. (1993) · Cardiovascular Research · doi:10.1093/cvr/27.3.341 · Cited by 480
Monocyte Chemoattractant Protein-1
Gu, L., Tseng, S. C., & Rollins, B. J. (1999) · Chemical Immunology and Allergy · doi:10.1159/000058723 · Cited by 326
Cited by
Mechanisms, Pathophysiology, and Therapy of Arterial Stiffness
Zieman, S. J., Melenovsky, V., & Kass, D. A. (2005) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000160548.78317.29 · Cited by 1,854
The pathogenesis of cardiac fibrosis
Kong, P., Christia, P., & Frangogiannis, N. G. (2014) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-013-1349-6 · Cited by 1,567
Frangogiannis, N. G. (2021) · Cardiovascular Research · doi:10.1093/cvr/cvaa324 · Cited by 1,229
Controversies in ventricular remodelling
Opie, L. H., Commerford, P. J., Gersh, B. J., & Pfeffer, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68074-4 · Cited by 861
Cardiac fibrosis: Cell biological mechanisms, molecular pathways and therapeutic opportunities
Frangogiannis, N. G. (2019) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2018.07.001 · Cited by 841
Metadata
- Authors
- Kuwahara, F., Kai, H., Tokuda, K., Takeya, M., Takeshita, A., Egashira, K., & Imaizumi, T.
- Venue
- Hypertension
- Published
- 2004-04
- Volume
- 43
- Issue
- 4
- Pages
- 739-745
- ISSN
- 0194-911X (ISSN-L)
- 1524-4563
- OpenAlex
- W2030968333
- Cited by
- 282
- References
- 21
- FWCI
- 7.23
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Hypertensive Myocardial Fibrosis and Diastolic Dysfunction: Another Model of Inflammation? https://app.cochat.ai/papers/10.1161/01.hyp.0000118584.33350.7d
- The paper
- Kuwahara, F., Kai, H., Tokuda, K., Takeya, M., Takeshita, A., Egashira, K., & Imaizumi, T. (2004). Hypertensive Myocardial Fibrosis and Diastolic Dysfunction: Another Model of Inflammation? Hypertension. https://doi.org/10.1161/01.hyp.0000118584.33350.7d
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.